ProCE Banner Activity

Bispecific Antibodies in the Management of Relapsed/Refractory Follicular Lymphoma

Slideset

Download this slideset from a live symposium for an expert overview of bispecific T-cell engager therapy in follicular lymphoma, including the latest clinical data, advice on CRS management with these agents, and future directions.

Released: December 07, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Genentech, a member of the Roche Group; Genmab; Ipsen Biopharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc.

Genentech, a member of the Roche Group

Genmab

Ipsen Biopharmaceuticals Inc

Regeneron Pharmaceuticals, Inc